GPC3 and liver cancer: The results for cabozantinib were affected by the same problem; its 2.90% sensitivity rate (2/69) in the in vitro HDS was all due to GPC-3 negative cases, and Wilcoxon's test found no significant difference in inhibition rates between GPC-3-negative and GPC-3-positive liver cancer cells, suggesting that this relationship is unlikely to be significant.